Expert Insights: Regimen Choice and Newly Approved Agents in Relapsed/Refractory Multiple Myeloma
Release Date: November 1, 2021
Expiration Date: October 31, 2022
This activity is intended for community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.
Upon completion of this activity learners should be able to:
- Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
- Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal antibody, bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
- Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with RRMM
- Discuss the results of clinical trials that are investigating emerging novel agents in patients with RRMM
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must:
1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Faculty and Planning Committee Disclosures
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
All faculty and planning committee members have no conflicts to disclose with the exception of the following:
Sagar Lonial, MD, FACP (Moderator)
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Consulting Fees: Amgen Inc., Bristol-Myers Squibb Company, Bluebird, Celgene Corporation, Genentech, Novartis, Sanofi, Takeda Oncology
Other: Board of directors TG Therapeutics with stock
Thomas Martin, MD
Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program
Director of Clinical Research
Associate Director, Myeloma Program, UCSF
Co-Leader, Cancer Immunology & Immunotherapy Program
Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Consultant Fees: GlaxoSmithKline LLC,
Research Funding to Institution: Amgen Inc, Janssen Oncology, Sanofi
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Dru Dace, PhD; Kraig Steubing
This activity is supported by educational grants from Bristol Myers Squibb and Oncopeptides, Inc.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.